

Precision Health Begins with Prevention

Clinically validated diagnostics powered by data-driven prediction



Global Burden of Diabetic Kidney Disease


With 40% of diabetic patients worldwide (nearly half-a-billion) developing kidney complications, it has never been more critical to shift from diagnosis to prevention.*¹

537m
diabetic patients
world-wide*²


40% (215m)
of diabetes patients will develop
kidney complications including ESRD

50%
ESRD patients die within 5
years & 20% die within 1 year*³

Up to **40%**



of high-risk patients in non-albuminuric / proteinuric DKD pt. are unidentified by current detection methods



IVD103 predicts the early critical shifts for the 3 key trajectories of kidney function in DKD

Adapted from Nat Rev Nephrol. 2021 (17)740-750.

DNLite in Clinical Use Peer-reviewed publication

1 Diabetes Kidney Disease

AJN
American Journal
of Nephrology
10.1159/000534514

Urinary Fetuin-A Fragments Predict Progressive eGFR Decline in Two Independent Type 2 Diabetes Cohorts of Different Ethnicities

Gwo-Tsann Chuang, Daan Kremer, Chi-Hsuan Huang, Firas F. Alkaff, Chih-Hung Lin, Tzu-Ling Tseng, Gozewijn Dirk Laverman, Stephan J. L. Bakker¹, Lee-Ming Chuang²

¹Division of Nephrology, Department of Internal Medicine,UMCG, Netherlands.

²Division of Endocrinology & Metabolism, Department of Internal Medicine, NTUH, Taipei, Taiwan

2 Kidney Transplant

AJN
American Journal
of Nephrology
10.1159/000534829

Urinary Post-Translationally Modified Fetuin-A Protein Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients

Firas F. Alkaff, Daan Kremera, Charlotte A. te Velde-Keyzer, Jacob van den Born, Stefan P. Berger,Gozewijn D. Laverman, Lee-Ming Chuang, Tzu-Ling Tseng², Stephan J.L. Bakker

¹Division of Nephrology, Department of Internal Medicine,UMCG, Netherlands.

²Bio Preventive Medicine Corp, Hsinchu, Taiwan

DKD/KT Prognosis Test

DNlite-IVD103 Human uPTM-FetA ELISA Test

Hearing the “Silent Phase” of Kidney Disease

We are conquering the world of kidney disease and kidney injury by translating validated and IP-protected novel biomarkers into clinically-validated solutions.



Regulatory Approvals


1 Diabetes Kidney Disease



2 Kidney Transplant



DNlite-IVD103 predicts progressive decline in advance



Progression of Nephropathy: Time after diagnosis (years)

J Clin Invest 2006; 116(2): 288-296.

DNlite-IVD103 predicts renal function loss years in advance through non-invasive ELISA-based testing. A new standard for kidney disease in clinics and labs.

DNlite-IVD103 Human uPTM-FetA ELISA Test

- ▶ Unique Single Urinary Biomarker
- ▶ Predict & Monitor Kidney Function Loss (eGFR decline)
- ▶ Multi-National Studies (2,000+ patients)
- ▶ Application: DKD, CKD, AKD, Kidney Transplant



About BPM

BIO PREVENTIVE MEDICINE is a leading company in renal biomarker area. As a clinical staged IVD and biotech company, BPM focuses on translating validated and IP-protected novel biomarkers into diagnostic solutions for unmet clinical needs. For more information, please refer to BPM official website or contact us.

Bio Preventative Medicine Corp.

<http://www.bpmbiotech.com>

dnlite@bpmbiotech.com